Kala enrolls first patient in PCED trial, closes $31M private placement

KALA BIO, Inc.

Enrolled first patient in CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect; top-line data targeted for Q1 2024.
Closed $31.0M private placement in December 2022, extending cash runway into Q1 2025.
Completed sale of EYSUVIS and INVELTYS to Alcon in Q3 2022 to focus on rare eye diseases.
Reported Q4 and FY2022 financial results; specific figures not available in the provided excerpt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 3, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022 and provided a general business update.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-002744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.